Apontis Pharma AG (APPH.DE)
- Previous Close
11.25 - Open
11.05 - Bid 11.05 x --
- Ask 11.30 x --
- Day's Range
11.05 - 11.25 - 52 Week Range
6.30 - 12.35 - Volume
803 - Avg. Volume
2,238 - Market Cap (intraday)
93.712M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
125.00 - EPS (TTM)
0.09 - Earnings Date Mar 28, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.
apontis-pharma.de137
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: APPH.DE
View MorePerformance Overview: APPH.DE
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APPH.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APPH.DE
View MoreValuation Measures
Market Cap
90.38M
Enterprise Value
74.93M
Trailing P/E
123.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.92
Price/Book (mrq)
3.01
Enterprise Value/Revenue
1.55
Enterprise Value/EBITDA
21.03
Financial Highlights
Profitability and Income Statement
Profit Margin
1.55%
Return on Assets (ttm)
1.47%
Return on Equity (ttm)
2.46%
Revenue (ttm)
48.47M
Net Income Avi to Common (ttm)
753.57k
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
15.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.6M